LLY

902.09

+0.98%↑

UNH

564.08

-0.18%↓

JNJ

161.69

+0.08%↑

ABBV

189.31

-0.33%↓

MRK

104.7

+0.43%↑

LLY

902.09

+0.98%↑

UNH

564.08

-0.18%↓

JNJ

161.69

+0.08%↑

ABBV

189.31

-0.33%↓

MRK

104.7

+0.43%↑

LLY

902.09

+0.98%↑

UNH

564.08

-0.18%↓

JNJ

161.69

+0.08%↑

ABBV

189.31

-0.33%↓

MRK

104.7

+0.43%↑

LLY

902.09

+0.98%↑

UNH

564.08

-0.18%↓

JNJ

161.69

+0.08%↑

ABBV

189.31

-0.33%↓

MRK

104.7

+0.43%↑

LLY

902.09

+0.98%↑

UNH

564.08

-0.18%↓

JNJ

161.69

+0.08%↑

ABBV

189.31

-0.33%↓

MRK

104.7

+0.43%↑

Начало・Списък с акции・Novo Nordisk A-S

Novo Nordisk A-S

Затворен

Сектор Здравеопазване

112.53 0.43

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

111.56

Максимум

113.16

Ключови измерители
By Trading Economics
Приходи	-5.4B 20B
Продажби	2.7B 68B
P/E Средно за сектора	49.94 112.16
EPS	4.49
Марж на печалбата	29.459
EBITDA	-1.2B 36B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+37.28 upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.4B 396B
Предишно отваряне	112.1
Предишно затваряне	112.53

Настроения в новините

By Acuity

96%

2 / 389 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

N/A / 117.81 Подкрепа & съпротива

Novo Nordisk A-S Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.09.2024 г., 19:26 ч. UTC

Значими двигатели на пазара

Skye Bioscience Shares Gain After Highlighting Safety of In-Development Obesity Treatment

26.10.2024 г., 11:00 ч. UTC

Топ новини

Heard on the Street: Pfizer's Activist Battle Might Fizzle -- but Its Stock Probably Won't -- WSJ

25.10.2024 г., 09:30 ч. UTC

Топ новини

Big Food Is Learning to Love Weight-Loss Drugs -- Heard on the Street -- WSJ

4.10.2024 г., 12:01 ч. UTC

Топ новини

As Weight-Loss Drugs Battle, Upstart Viking -2-

4.10.2024 г., 12:01 ч. UTC

Топ новини

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

3.10.2024 г., 14:45 ч. UTC

Топ новини

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3.10.2024 г., 13:12 ч. UTC

Топ новини

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3.10.2024 г., 12:51 ч. UTC

Пазарно говорене

Novo Nordisk's Weight-Loss Jab Trial Will Be Defining -- Market Talk

2.10.2024 г., 13:48 ч. UTC

Печалби

Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com

2.10.2024 г., 12:28 ч. UTC

Пазарно говорене

Novo Nordisk Shares Unlikely to Move Ahead of New Drug Data -- Market Talk

2.10.2024 г., 09:00 ч. UTC

Пазарно говорене

Novo Nordisk's New Weight-Loss Jab Could Support Co Into 2030s -- Market Talk

26.09.2024 г., 13:15 ч. UTC

Пазарно говорене

Novo Nordisk's Share Price Looks Capped Ahead of New Drug Data -- Market Talk

26.09.2024 г., 11:51 ч. UTC

Пазарно говорене

Novo Nordisk Senate Hearing Removes a Share Overhang -- Market Talk

23.09.2024 г., 10:37 ч. UTC

Топ новини

Fed Uncertainty Is History. Now Markets Need to Brace for Election Volatility. -- Barrons.com

23.09.2024 г., 10:37 ч. UTC

Топ новини

Fed Uncertainty Is History. Now Markets Need to -2-

20.09.2024 г., 16:30 ч. UTC

Пазарно говорене

'Knee-Jerk' Corbus Selloff Seen as Buying Opportunity -- Market Talk

20.09.2024 г., 13:55 ч. UTC

Топ новини

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20.09.2024 г., 12:46 ч. UTC

Топ новини

Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20.09.2024 г., 09:30 ч. UTC

Топ новини

The Price War in Weight-Loss Drugs Is Here -- WSJ

12.09.2024 г., 13:00 ч. UTC

Топ новини

Senators Target Influencers, Telehealth Firms for Misleading Weight-Loss and Other Drug Promotion -- WSJ

12.09.2024 г., 11:45 ч. UTC

Пазарно говорене

Печалби

Novo Nordisk's Obesity Pill Data Confirm Investor Optimism -- Market Talk

12.09.2024 г., 10:30 ч. UTC

Пазарно говорене

Печалби

Novo Nordisk's Amycretin Obesity Pill Slightly Disappoints on Safety -- Market Talk

11.09.2024 г., 12:08 ч. UTC

Топ новини

Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids -- Barrons.com

9.09.2024 г., 07:56 ч. UTC

Пазарно говорене

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

3.09.2024 г., 11:09 ч. UTC

Топ новини

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27.08.2024 г., 05:30 ч. UTC

Топ новини

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14.08.2024 г., 12:01 ч. UTC

Пазарно говорене

Печалби

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9.08.2024 г., 11:30 ч. UTC

Топ новини

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9.08.2024 г., 07:30 ч. UTC

Пазарно говорене

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8.08.2024 г., 15:44 ч. UTC

Топ новини

Печалби

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Novo Nordisk A-S Прогноза

Ценова цел

By TipRanks

37.28% нагоре

12-месечна прогноза

Среден 154.25 USD 37.28%

Висок 160 USD

Нисък 146 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Novo Nordisk A-S през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Novo Nordisk A-S през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 117.81Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

2 / 389 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

Относно Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.